Drug Profile
Stannsoporfin - Mallinckrodt
Alternative Names: Sn-mesoporphyrin; Stanate; tin-mesoporphyrin; TorcanLatest Information Update: 23 Mar 2020
Price :
$50
*
At a glance
- Originator Rockefeller University
- Developer InfaCare Pharmaceutical Corporation; National Hospital of Pediatrics
- Class Antirheumatics; Heavy metals; Hepatoprotectants; Mesoporphyrins
- Mechanism of Action Decyclizing heme oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperbilirubinaemia
Most Recent Events
- 28 Feb 2020 InfaCare Pharmaceuticals completes the JASMINE-205 extension trial for Hyperbilirubinaemia (In neonates, In infants, In children) in the US (NCT02000830)
- 28 Jun 2019 Discontinued - Phase-II for Hyperbilirubinaemia (In neonates) in Poland, Ukraine, Vietnam, Spain (IM)
- 28 Jun 2019 Discontinued - Preregistration for Hyperbilirubinaemia (In neonates) in USA (IM)